Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Operating Officer | February 15, 2018 | February 23, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,612 |
Ending reported balance
After 2018-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 16,152 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 9,460 · Balance 25,612 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
Quince Therapeutics, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2030-06-07 | Direct | 11,029 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 11,029 · Balance 11,029 F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 15,400 | $47.96 | $738,585.54 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,868 F4 · price: Sale prices reported for the transactions reported here range from $47.50 to $48.20. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,600 | $46.83 | $683,735.52 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,268 F3 · price: Sale prices reported for the transactions reported here range from $46.30 to $47.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2009 Filed Apr 7, 2009 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-09-006327 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,948 | $44.04 | $261,949.92 |
DisclosureSEC source: 0001179110-09-005161 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,868 Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-005161 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,816 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 12, 2009. Read SEC document |
| January 21, 2009 Filed Jan 24, 2009 02:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 92,400 | $0.00 Strike: $47.20 | $0.00 |
DisclosureSEC source: 0001179110-09-001500 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,400 Underlying: Common Stock · 92,400 shares Expires 2019-01-21 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 21, 2010 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 21, 2014. Read SEC document |
| January 07, 2009 Filed Jan 8, 2009 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-09-000801 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on November 2, 2005, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| January 07, 2009 Filed Jan 8, 2009 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-000801 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| January 07, 2009 Filed Jan 8, 2009 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 30,000 | $49.86 | $1,495,743.00 |
DisclosureSEC source: 0001179110-09-000801 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 Read SEC document |
| January 07, 2009 Filed Jan 8, 2009 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-09-000801 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2009 Filed Jan 8, 2009 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-09-000801 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · derivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options vested 20% on November 2, 2005, the first anniversary of the grant. The balance vests quarterly thereafter until it fully vests on November 2, 2009. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested 20% on January 26, 2006, the first anniversary of the grant. The balance vests quarterly thereafter until it fully vests on January 26, 2010. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,000 | $45.69 | $913,788.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 F2 · price: Sale prices reported for the transactions reported here range from $45.28 to $45.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $44.97 | $449,747.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,816 F1 · price: Sale prices reported for the transactions reported here range from $44.79 to $45.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2008 Filed Oct 8, 2008 22:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-08-018006 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2008 Filed Oct 14, 2008 16:46 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,000 | $45.73 | $914,550.00 |
DisclosureSEC source: 0001179110-08-018132 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 F2 · price: Sale prices reported for the transactions reported here range from $45.58 to $45.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 06, 2008 Filed Oct 14, 2008 16:46 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $45.06 | $450,636.00 |
DisclosureSEC source: 0001179110-08-018132 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,816 F1 · price: Sale prices reported for the transactions reported here range from $44.79 to $45.58. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · derivative · entry 12 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested over a five year period with 20% vesting November 2, 2005, the first anniversary of the grant. The options continued to vest in quarterly installments over the next four years, and will be fully vested on November 2, 2009. Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · derivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested over a five year period with 20% vesting January 26, 2006, the first anniversary of the grant. The options continued to vest in quarterly installments over the next four years, and will be fully vested on January 26, 2010. Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,760 | $51.80 | $453,768.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $51.77 | $10,354.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,576 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,800 | $51.78 | $611,004.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,776 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $51.70 | $103,400.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,576 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $51.75 | $129,375.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,576 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $51.80 | $155,400.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,076 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $51.95 | $10,390.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,076 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,540 | $52.00 | $80,080.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,276 Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2008 Filed Jul 10, 2008 18:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-08-013542 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following the reported transaction includes 792 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2008. Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · derivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a five year period with 20% vesting November 2, 2005, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on November 2, 2009. Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · derivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest over a five year period with 20% vesting January 26, 2006, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on January 26, 2010. Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 12,500 | $51.50 | $643,750.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,024 Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,200 | $51.51 | $422,382.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,524 Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,500 | $51.52 | $283,360.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,724 Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,800 | $51.60 | $196,080.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,224 Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2008 Filed Apr 14, 2008 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-08-007761 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2008 Filed Mar 19, 2008 22:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 5,715 | $47.55 | $271,748.25 |
DisclosureSEC source: 0001179110-08-006304 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,024 Read SEC document |
| March 17, 2008 Filed Mar 19, 2008 22:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-08-006304 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,739 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 17, 2008. Read SEC document |
| January 30, 2008 Filed Feb 1, 2008 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $43.15 | $0.00 |
DisclosureSEC source: 0001179110-08-002129 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2018-01-30 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013. Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · derivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vest over a five year period with 20% vesting November 2, 2005, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on November 2, 2009. Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · derivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a five year period with 20% vesting January 26, 2006, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on January 26, 2010. Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $46.70 | $140,100.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $46.74 | $140,220.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $46.75 | $233,750.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $46.77 | $93,540.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,739 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.